1 / 2

Psoriatic Arthritis Market

Psoriatic Arthritis is a sort of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but joint problems can sometimes begin before skin patches appear.

DelveInsight
Download Presentation

Psoriatic Arthritis Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Psoriatic Arthritis is a sort of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but joint problems can sometimes begin before skin patches appear. Psoriatic Arthritis Sign and Symptoms Psoriatic arthritis and psoriasis are chronic diseases that worsen over time, but you'll have periods when your symptoms improve with time. The signs and symptoms of psoriatic arthritis often resemble those of rheumatoid arthritis. However, psoriatic arthritis causes swollen fingers and toes, pain in feet, lower back pain, etc. Psoriatic Arthritis Medications available are: ●Nonsteroidal anti-inflammatory drugs (NSAIDs) ●Disease-modifying antirheumatic drugs (DMARDs) ●Immunosuppressants ●Biologic agents ●Newer oral medication-Apremilast (Otezla) Psoriatic Arthritis Epidemiology Insights As per the estimates by DelveInsight, there is no gender based difference but prevalence of severe cases is the highest followed by moderate and mild. Psoriatic Arthritis was identified in 431 of 3021 patients with psoriasis, with a mean prevalence

  2. of 14.3 percent in Japan. Assessments as per DelveInsight’s analysts showed that diagnosed cases for is expected to increase in 2030 owing to the increased awareness with educational campaigns and an interdisciplinary approach to managing the condition between dermatologists and rheumatologists. Click here and know more about Psoriatic Arthritis Market Outlook 2030 Psoriatic Arthritis Market Insights Psoriatic Arthritis treatments aren’t one-size-fits-all; the current treatment strategy in Psoriatic Arthritis emphasizes a target to target approach to the prevalent domains. Advances in the knowledge of pathogenesis have led to the development of novel biologics beyond anti-TNFs. However, there is still a substantial proportion of patients who may not respond to certain treatment options. The current practice relies on the individualizing choice of treatment by matching the most severely affected domains of the patients with the best available evidence of efficacies of drugs for those domains. When patients do not respond to treatment, shifting and cycling through different options would be the rational steps. The present emerging Psoriatic Arthritis market consists of interleukin-23, Tyrosine Kinase inhibitors, JAK inhibitors. The key pharmaceutical players are UCB Biopharma, AbbVie, Bristol- Myers Squibb, Sun Pharma and others. It is expected that launch of these drugs would offer more option to patients who currently poorly responds to oral small molecules and TNF inhibitors. Got queries? Read more @ Psoriatic Arthritis Market Landscape About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

More Related